Arcus Biosciences, Inc.

NYSE:RCUS Voorraadrapport

Marktkapitalisatie: US$1.4b

Arcus Biosciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Arcus Biosciences heeft een totaal eigen vermogen van $635.0M en een totale schuld van $20.0M, wat de schuld-eigenvermogensverhouding op 3.1% brengt. De totale activa en totale passiva bedragen respectievelijk $1.2B en $551.0M.

Belangrijke informatie

3.1%

Verhouding schuld/eigen vermogen

US$20.00m

Schuld

Rente dekkingsration/a
ContantUS$969.00m
AandelenUS$635.00m
Totaal verplichtingenUS$551.00m
Totaal activaUS$1.19b

Recente financiële gezondheidsupdates

Recent updates

Arcus Biosciences: Advancing On Several Fronts

Oct 29

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05
Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $1.0B ) RCUS } overtreffen de korte termijn passiva ( $199.0M ).

Langlopende schulden: De kortetermijnactiva RCUS ( $1.0B ) overtreffen de langetermijnschulden ( $352.0M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: RCUS heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van RCUS is de afgelopen 5 jaar gestegen van 0% naar 3.1%.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: RCUS heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: RCUS heeft voldoende kasruimte voor 2.9 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 10.2 % per jaar.


Ontdek gezonde bedrijven